Glenmark Pharmaceuticals is currently trading at Rs. 904.50, up by 2.90 points or 0.32% from its previous closing of Rs. 901.60 on the BSE.
The scrip opened at Rs. 902.30 and has touched a high and low of Rs. 909.95 and Rs. 901.60 respectively. So far 6324 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs. 729.30 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 944.10 and Rs. 896.50 respectively. The current market cap of the company is Rs. 25511.79 crore.
The promoters holding in the company stood at 46.49%, while Institutions and Non-Institutions held 41.24% and 12.27% respectively.
Glenmark Pharmaceuticals, a global pharmaceutical company, has received US Food and Drug Administration (USFDA) clearance for its Investigational New Drug (IND) application to begin a Phase 2 study of GSP 304 (tiotropium bromide) for administration by nebulization for the long term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
The company plans to initiate clinical development with a Phase 2 study of GSP 304, a new orally administered formulation, in subjects with mild to moderate COPD, as determined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The efficacy, pharmacokinetics, and safety profiles of currently available formulations of tiotropium bromide are well established.
Glenmark Pharmaceuticals is a global innovative pharmaceutical company with operations in more than 80 countries. It has a diverse pipeline with several compounds in various stages of clinical development primarily focused in the areas of oncology, respiratory disease, and dermatology.